Online ISSN: 2515-8260

Keywords : Rifampicin

Antitubercular Drug Induced Hepatotoxicity: A Review

Manjot Kaur Gill; Rakesh Raman Patyar; Sazal Patyar

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 2840-2847

Hepatotoxicity is an emerging medical problem. It has multiple etiological factors but most common reason is chronic treatment with certain drugs during the cure of numerous life threatening diseases. Antitubercular drugs are the leading cause of injury or damage to liver. So this is a challenging task to prevent the drug induced hepatotoxicity during tuberculosis treatment. Generally it results into interruption of treatment and cause re-emergence of this disease. This review article highlights the different mechanisms of anti-tubercular drug induced hepatotoxicity, its incidence and clinical management.

Development Of Rifampicin Loaded Hyaluronic Acid Coated Chitosan Nanoparticles

Suchita Prabhakar Dhamane; Swati Changdeo Jagdale

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 1, Pages 3447-3458

There is a promising potential for nanoparticles in developing controlled and guided drug delivery systems. The most effective formulations are currently considered to be chitosan based nanoparticles; biocompatible, biodegradable, less toxic and simple to use in preparations. Chitosan is a natural biopolymer and has many advantages that can easily be used to achieve the ideal drug delivery mechanism. It is licensed and classified in General Safe (GRAS) by U.S. Food and Drug Administration (USFDA). In the current study, chitosan nanoparticles loaded with Rifampicin were prepared and published in-house. Hyaluronic acid (HA) was coated and further characterized using effective in-vitro methods. The research also included the determination of pharmacokinetic parameters. The findings were confirmatory and can be used to increase the accumulation of medicines.